Quantcast

Here's Why You Should Buy Integra LifeSciences (IART) Stock


Shutterstock photo

Integra LifeSciences Holdings Corporation IART has been gaining investor confidence on consistently positive results. In the past six months, the company's share price has outperformed its  industry . The stock has surged 33.3% against the industry's 6.2% fall.

This leading developer, manufacturer and marketer of cost-effective surgical implants and medical instruments has a market cap of $5.86 billion. The company has an earnings growth rate of 13.90% for the next three to five years.

With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. 

The company's estimate revision trend for the current year has been northbound. In the past 60 days, 10 analysts have revised their estimates upward while there was no movement in the opposite direction. Resultantly, earnings estimates rose around 3.4% to $2.41.

Let's find out whether the recent positive trend is a sustainable one.

Global Prospects Impressive

In spite of facing foreign exchange fluctuations across its international business, Integra LifeSciences has been successfully seeing certain key developments on the overseas front. The company is looking forward to investment opportunities in the Asian market in order to grow business much faster than the United States and also across certain parts of its international businesses.

In line with this growth strategy, the company is preparing to launch several products in China and Japan. Turning to Europe, management feels encouraged about the growth potential of this region with Tissue Technologies business and CUSA Clarity product scheduled to be launched in Europe.

Strength in Regenerative Technologies

Integra LifeSciences' Regenerative Technologies is the largest franchise under Orthopedics and Tissue Technologies. In the first quarter of 2018, the company registered mid-single digit's growth in this franchise, primarily banking on strength in the PriMatrix product lines, which increased in double digits in both inpatient and outpatient settings.

Earlier, Integra LifeSciences introduced several new products having expanded the company's portfolio of solutions in the United States hernia repair market and in the European breast reconstruction market. This should further spur growth in 2018.

Solid Growth at Codman Specialty Surgical (CSS) Segment

At the end of the first quarter, Integra LifeSciences noted that the performance in Codman Specialty Surgical segment exceeded its expectations. It has also successfully completed the transition of the Codman business in China where this business boasts its largest revenue base. Also, it has integrated sales territories associated with above 90% of the Codman revenue globally by the end of the first quarter. This apart, the company has opened a new campus in Mansfield, MA, which will be home to the conveying Codman teammates.

Integra LifeSciences experienced 2.5% organic growth in the Codman Specialty Surgical segment during first-quarter 2018. This can be attributed to the integration progress around the globe. This apart, with the recent addition of Codman's commercial resources, the company is well-poised to accelerate growth in Dural Repair during 2018.

Other Key Picks

Other top-ranked stocks in the broader medical space include Genomic Health GHDX , Abiomed ABMD and Stryker Corp. SYK .

Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1 (Strong Buy). You can see  the complete list of today's Zacks #1 Rank stocks here .

Abiomed has a projected long-term earnings growth rate of 27% and a Zacks Rank of 1.

Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank of 2.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ABIOMED, Inc. (ABMD): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

Genomic Health, Inc. (GHDX): Free Stock Analysis Report

Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
Referenced Symbols: ABMD , SYK , GHDX , IART



More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research










Research Brokers before you trade

Want to trade FX?